Prestige Consumer Healthcare Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Prestige Consumer Healthcare Inc (PBH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Prestige Consumer Healthcare Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,105M vs 319,142M combined for its competitors (0.3% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-3.8% annualized vs trailing 12 months), vs holding steady (+0.2%) for its tracked peer group.
- Growth: Prestige Consumer Healthcare Inc generated 6.6% revenue growth year over year in Q1 2026, vs 5.0% for its competitors combined.
- Profitability: Its 25.5% net margin compares with 17.3% for the peer group.
- Scale: Prestige Consumer Healthcare Inc ranks #89 of 548 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Prestige Consumer Healthcare Inc accounted for 0.3% of combined revenue among its tracked peer group, up from 0.3% a year earlier.
- Peer differentiation: Revenue per employee of $1.94M compares with $0.74M for the peer group (2.6x).
- Structure: Prestige Consumer Healthcare Inc operates in the following segments: North American OTC Healthcare, International OTC Healthcare.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
PBH Sales vs. its Competitors, Q1 2026
Prestige Consumer Healthcare Inc reported revenue growth of 6.57 % year on year in Q1 2026, above its competitors' combined revenue growth of 4.99 %.
With a net margin of 25.49 %, Prestige Consumer Healthcare Inc achieved higher profitability than its competitors (17.32 %).
Prestige Consumer Healthcare Inc generated 0.33 % of the combined sales of its peer group, up from 0.33 % a year earlier.
Prestige Consumer Healthcare Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Prestige Consumer Healthcare Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Prestige Consumer Healthcare Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Prestige Consumer Healthcare Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Prestige Consumer Healthcare Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 6.6% for Prestige Consumer Healthcare Inc. Prestige Consumer Healthcare Inc's share of combined industry revenue moved from 0.05% to 0.05%, a gain of 0.00 percentage points.
Prestige Consumer Healthcare Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Prestige Consumer Healthcare Inc | Yes | No | No | Yes |
| Competitors combined (16) | ||||
| High-Confidence Competitors (9) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PBH Stock Performance relative to its Competitors
PBH Stock Performance relative to High-Confidence Competitors
PBH Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Compass Diversified Holdings | 282.9% | Outperformed |
| 2 | Belite Bio Inc | 282.9% | Outperformed |
| 3 | Johnson and Johnson | 282.9% | Outperformed |
| 4 | Kenvue Inc | 282.9% | Outperformed |
| 5 | Abbvie Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Prestige Consumer Healthcare Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Prestige Consumer Healthcare Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Prestige Consumer Healthcare Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Prestige Consumer Healthcare Inc |
2,358.30 | 1,104.96 |
 Johnson and Johnson |
651,743.86 | 99,335.00 |
 Abbvie Inc |
506,792.00 | 66,014.00 |
 Procter and Gamble Co |
390,110.83 | 87,922.00 |
 Haleon Plc |
79,789.84 | 14,550.63 |
 Colgate palmolive Company |
76,467.31 | 21,284.00 |
| SUBTOTAL | 1,914,134.66 | 396,471.66 |
Sign in to see all competitors of Prestige Consumer Healthcare Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Prestige Consumer Healthcare Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Prestige Consumer Healthcare Inc's Competitors Named by the Company
Competitive relationships identified from Prestige Consumer Healthcare Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| AbbVie | Company report | 85% |
| Alcon | Company report | 85% |
| Amazon | Company report | 85% |
| Walmart | Company report | 85% |
| Combe | Company report | 85% |
| Bausch Health Companies Inc. | Company report | 85% |
| Mondel | Company report | 85% |
| GlaxoSmithKline | Company report | 85% |
| Bayer | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Sunstar America, Inc. | Company report | 85% |
| The Procter & Gamble Company | Company report | 85% |
| Reckitt Benckiser | Company report | 85% |
| Novabridge Biosciences | Company report | 85% |
| Compass Diversified Holdings | Company report | 85% |
| Haleon Plc | Company report | 85% |
| Sanofi | Company report | 85% |
| Kenvue Inc | Company report | 85% |
| Kimberly clark Corporation | Company report | 85% |
| Colgate palmolive Company | Company report | 85% |
| Church and Dwight Co Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Prestige Consumer Healthcare Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Prestige Consumer Healthcare Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Prestige Consumer Healthcare Inc | North American OTC Healthcare 83.92 % |
| Johnson and Johnson | Oncology 29.93 % |
| Procter and Gamble Co | Fabric & Home Care 35.25 % |
| Colgate palmolive Company | Oral, Personal and Home Care 77.56 % |
| Kenvue Inc | Self Care 42.61 % |
| Kimberly clark Corporation | North America (NA) 64.41 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Prestige Consumer Healthcare Inc .
Prestige Consumer Healthcare Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Prestige Consumer Healthcare Inc | 2,358 | 1,938,521 | 712,758 |
| Johnson and Johnson | 651,744 | 705,504 | 114,311 |
| Abbvie Inc | 506,792 | 1,158,140 | 181,509 |
| Procter and Gamble Co | 390,111 | 845,404 | 154,750 |
| Haleon Plc | 79,790 | 145,506 | 22,162 |
| Colgate palmolive Company | 76,467 | 633,452 | 63,899 |
| PEERS TOTAL | 1,911,776 | 741,438 | 114,711 |
Sign in to see all peers for Prestige Consumer Healthcare Inc .
Prestige Consumer Healthcare Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Prestige Consumer Healthcare Inc | United States 78.12 % |
| Johnson and Johnson | United States 58.90 % |
| Procter and Gamble Co | Non-US 52.05 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Prestige Consumer Healthcare Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 497 companies in Prestige Consumer Healthcare Inc's industry classification, broader than the peer set above. Market cap in millions of $.Prestige Consumer Healthcare Inc ranks #89 of 497 companies by market capitalization in its industry, holding 0.04 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 896, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,259,563 | 21.86 % |
| 2 | Johnson and Johnson | 649,481 | 11.27 % |
| 3 | Beone Medicines Ltd | 534,403 | 9.28 % |
| 4 | Abbvie Inc | 506,506 | 8.79 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 89 | Prestige Consumer Healthcare Inc | 2,358 | 0.04 % |
Market cap and industry share for the rest of Prestige Consumer Healthcare Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-03.
Prestige Consumer Healthcare Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 84 | Nurix Therapeutics Inc | 2,868 | 104.87 % |
| 85 | Silence Therapeutics Plc | 2,803 | 176.40 % |
| 86 | Mbx Biosciences Inc | 2,623 | 156.53 % |
| 87 | Newamsterdam Pharma Company N v | 2,439 | -47.05 % |
| 88 | Arcus Biosciences Inc | 1,234 | 12.3% |
| 89 | Prestige Consumer Healthcare Inc | 2,358 | -18.80 % |
| 90 | Biohaven Ltd | 1,234 | 12.3% |
| 91 | Xencor Inc | 1,234 | 12.3% |
| 92 | Immunome Inc | 1,234 | 12.3% |
| 93 | Aurinia Pharmaceuticals Inc | 1,234 | 12.3% |
| 94 | Vera Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Prestige Consumer Healthcare Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-03. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Prestige Consumer Healthcare Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (339 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.54 % | 20.18 % (avg) | -19.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -3.03 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 1.27 % | 5.31 % (avg) | -4.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Prestige Consumer Healthcare Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (339 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 14.5x | 28.4x | -13.9x |
| EV / EBITDA | 8.0x | 16.3x | -8.3x |
| P/B | 1.3x | 4.1x | -2.7x |
| Return on Equity | 0.09 % | industry aggregate | -17.06 % |
| Return on Invested Capital | - | -4.48 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Prestige Consumer Healthcare Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -3.43 % | -3.83 % | 0.42 % | 10.53 % | 4.84 % | 2.14 % | -1.26 % | -1.34 % |
| Operating Margin | 20.00 % | 6.69 % | 31.39 % | 30.58 % | 30.30 % | -1.83 % | 29.55 % | 29.22 % |
| Return on Invested Capital | 4.05 % | 1.44 % | 6.01 % | 6.07 % | 5.99 % | -0.41 % | 6.24 % | 5.78 % |
| P/E | 27.3x | - | 11.1x | 16.0x | 14.8x | - | 18.1x | 16.2x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Prestige Consumer Healthcare Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Prestige Consumer Healthcare Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 7.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Prestige Consumer Healthcare Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 896 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.27 % vs industry average 5.31 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Prestige Consumer Healthcare Inc's dedicated Suppliers and Customers pages, not here.
Prestige Consumer Healthcare Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Prestige Consumer Healthcare Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Prestige Consumer Healthcare Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 17.1 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-3.8% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Prestige Consumer Healthcare Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Prestige Consumer Healthcare Inc | 0.72 | 3.63 | 0.67 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Procter and Gamble Co | 0.26 | 0.71 | 0.71 |
| Haleon Plc | 0.27 | 0.92 | 0.47 |
| Colgate palmolive Company | 0.22 | 0.96 | 15.33 |
Sign in to see all peers for Prestige Consumer Healthcare Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Prestige Consumer Healthcare Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Prestige Consumer Healthcare Inc | Q2 2026 | +6.6 % | -38.0 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Abbvie Inc | Q2 2026 | +10.3 % | +2,143.6 % |
| Procter and Gamble Co | Q3 2026 | +4.0 % | -1.0 % |
| Haleon Plc | Q4 2025 | +1.3 % | +17.6 % |
| Colgate palmolive Company | Q3 2026 | +4.6 % | -2.0 % |
| PEERS TOTAL | +6.6 % | +8.3 % |
Sign in to see all peers for Prestige Consumer Healthcare Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Prestige Consumer Healthcare Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Prestige Consumer Healthcare Inc | Q2 2026 | +18.8 % | +341.9 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Abbvie Inc | Q2 2026 | -19.2 % | -21.0 % |
| Procter and Gamble Co | Q3 2026 | +7.3 % | +13.8 % |
| Haleon Plc | Q4 2025 | -7.4 % | +32.9 % |
| Colgate palmolive Company | Q3 2026 | +2.6 % | -13.5 % |
Sign in to see all peers for Prestige Consumer Healthcare Inc .
Prestige Consumer Healthcare Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Prestige Consumer Healthcare Inc | 10.90% | 10.06% | 21.77% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Abbvie Inc | 7.48% | 12.87% | - |
| Procter and Gamble Co | 12.54% | 17.47% | 29.71% |
| Haleon Plc | 5.05% | 8.42% | 10.00% |
| Colgate palmolive Company | 12.92% | 20.06% | 417.50% |
Sign in to see all peers for Prestige Consumer Healthcare Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Prestige Consumer Healthcare Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Prestige Consumer Healthcare Inc | 13.95 | 2.13 |
| Johnson and Johnson | 40.27 | 6.56 |
| Abbvie Inc | 49.23 | 7.68 |
| Procter and Gamble Co | 24.52 | 4.44 |
| Haleon Plc | 47.78 | 5.48 |
| Colgate palmolive Company | 37.42 | 3.59 |
| PEERS AVERAGE | 31.09 | 4.83 |
Sign in to see all peers for Prestige Consumer Healthcare Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.